Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of diabetes mellitus (Type 1 or Type 2)~* Hemoglobin A1c (HbA1c) of less than or equal to (≤) 10% within 2 months prior to Day 1~* Macular thickening secondary to diabetic macular edema (DME) involving the center of the fovea~* Decreased visual acuity attributable primarily to DME~* Ability and willingness to undertake all scheduled visits and assessments~* For women of childbearing potential: agreement to remain abstinent or use acceptable contraceptive methods that result in a failure rate of \<1% per year during the treatment period and for at least 3 months after the final dose of study treatment~Exclusion Criteria:~* Currently untreated diabetes mellitus or previously untreated patients who initiated oral or injectable anti-diabetic medication within 3 months prior to Day 1~* Uncontrolled blood pressure, defined as a systolic value greater than (\>)180 millimeters of mercury (mmHg) and/or a diastolic value \>100 mmHg while a patient is at rest~* Currently pregnant or breastfeeding, or intend to become pregnant during the study~* Treatment with panretinal photocoagulation or macular laser within 3 months prior to Day 1 to the study eye~* Any intraocular or periocular corticosteroid treatment within the past 6 months prior to Day 1 to the study eye~* Prior administration of IVT faricimab in either eye~* Active intraocular or periocular infection or active intraocular inflammation in the study eye~* Any current or history of ocular disease other than DME that may confound assessment of the macula or affect central vision in the study eye~* Any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than DME in the study eye~* Other protocol-specified inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: Faricimab 6 mg Q8W (Type: EXPERIMENTAL): Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.
- B: Faricimab 6 mg PTI (Type: EXPERIMENTAL): Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections once every 4 weeks (Q4W), 8 weeks (Q8W), 12 weeks (Q12W), or 16 weeks (Q16W) up to Week 96, followed by the final study visit at Week 100.
- C: Aflibercept 2 mg Q8W (Type: ACTIVE_COMPARATOR): Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete